Abstract：
Despite the lack of approved anti-angiogenic therapies in squamous cell carcinoma of the head and neck (SCCHN), preclinical and more recent clinical evidence support the role of targeting the vascular endothelial growth factor (VEGF) in this disease. Targeting VEGF has gained even greater interest following the recent evidence supporting the role of immunotherapy in the management of advanced SCCHN. Preclinical evidence strongly suggests that VEGF plays a role in promoting the growth and progression of SCCHN, and clinical evidence exists as to the value of combining this strategy with immunotherapeutic agents. Close to 90% of SCCHNs express VEGF, which has been correlated with a worse clinical prognosis and an increased resistance to chemotherapeutic agents. As immunotherapy is currently at the forefront of the management of advanced SCCHN, revisiting the rationale for targeting angiogenesis in this disease has become an even more attractive proposition.
摘要：
尽管头颈部鳞状细胞癌（SCCHN）缺乏批准的抗血管生成疗法，临床前和最近的临床证据支持靶向血管内皮生长因子(VEGF)在该疾病中的作用.在最近的证据支持免疫疗法在晚期SCCHN的管理中的作用之后,靶向VEGF获得了甚至更大的兴趣。临床前证据强烈表明VEGF在促进SCCHN的生长和进展中起作用。和临床证据表明，将这种策略与免疫治疗剂相结合的价值。接近90%的SCCHN表达VEGF,这与较差的临床预后和对化学治疗剂的耐药性增加有关。由于免疫疗法目前处于先进SCCHN管理的最前沿，重新审视在这种疾病中靶向血管生成的基本原理已成为一个更具吸引力的命题.
